Abcam, ab257379, Human CAPN2 (Calpain 2) knockout HEK-293T cell lysate

Size: 1Kit
CAPN2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 4 and 1 bp insertion in exon 4 and 47 bp deletion in exon 4 and 8 bp deletion in exon 4.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 4 and 1 bp insertion in exon 4 and 47 bp deletion in exon 4 and 8 bp deletion in exon 4.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CAPN2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Calpain 2 also known as CAPN2 or calpain-2 is a heterodimer protease enzyme weighing around 80 kDa. It belongs to the calpain family which requires calcium ions for activation. Calpain 2 expresses in many tissues including the brain muscles and liver indicating its widespread role in cellular processes. The enzyme comprises a large catalytic subunit and a small regulatory subunit each encoded by different genes.
Biological function summary
Calpain-2 plays a significant role in cell signaling cytoskeletal remodeling and apoptosis regulation. It does not typically function in isolation but partners with other molecules forming complexes necessary for precise proteolytic activity. This enzyme modulates several cell functions by cleaving substrates like cytoskeletal proteins transcription factors and enzymes which allows cells to respond adaptively to various stimuli.
Pathways
Calpain-2 integrates into important signaling cascades such as the ERK and PI3K/AKT pathways. It influences these pathways by processing specific proteins and modifying their activity thereby affecting cell survival and proliferation. Calpain-2 closely interacts with proteins like phosphatidylinositol-45-bisphosphate 3-kinase (PI3K) and extracellular signal-regulated kinases (ERKs) within these pathways emphasizing its importance in finely-tuning cellular responses.
Calpain-2 links to several pathological conditions including neurodegenerative diseases like Alzheimer's and muscular disorders such as Duchenne Muscular Dystrophy. In Alzheimer's disease calpain-2 activity influences the processing of amyloid precursor proteins contributing to plaque formation. In Duchenne Muscular Dystrophy calpain-2 activity disrupts muscle fiber integrity through its interaction with proteins like dystrophin aggravating the disorder's progression.